Saturday 17 October 2026
Export SENS’s income statement to Excel — free account
Senseonics Holdings, Inc.
SENS Healthcare Medical Devices
Senseonics Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.3 million, up 56.9% from fiscal 2024. In the quarter to June 2026, revenue grew 117.8%, EPS fell 57.5%, free cash flow fell 223.2% and total debt rose 58.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
7.85
0.38
−4.62%
Follow SENS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
6.77 | 7.50 | 6.53 | 13.38 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.90) | (9.53) | (12.82) | (24.78) | |
P/B ratio |
3.64 | 8.89 | 3.77 | 5.02 | |
Price to Tangible BV |
3.64 | 8.89 | 3.77 | 5.02 | |
EV/Sales |
5.55 | 7.48 | 5.66 | 11.74 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.81) | (4.06) | (3.38) | (6.21) | |
EV/FCF |
(2.78) | (4.01) | (3.31) | (6.13) | |
Quick Ratio |
6.21 | 3.01 | 4.37 | 5.62 | |
Current Ratio |
6.74 | 3.51 | 4.83 | 6.23 | |
Net Debt/EBITDA |
2.46 | 0.92 | 2.86 | 3.95 | |
Debt/Assets |
31.56% | 34.91% | 28.18% | 25.20% | |
Debt/Equity |
0.62 | 1.05 | 0.58 | 0.45 | |
Asset Turnover |
0.30 | 0.43 | 0.31 | 0.25 | |
Operating CF/Net income |
0.82 | 0.99 | 0.86 | 0.81 | |
Capex/Depreciation |
(0.40) | (0.20) | (1.03) | (0.44) | |
Interest Coverage |
(22.49) | (26.72) | (17.35) | (16.74) | |
Research and Development Expense of Revenue |
80.36% | 73.53% | 61.86% | 95.85% | |
Selling, General and Administrative Expense of Revenue |
227.22% | 257.66% | 138.71% | 189.13% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
24.64% | 19.43% | 18.41% | 34.53% | |
Graham Net Nets |
0.24 | 0.08 | 0.23 | 0.18 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(39.26%) | (30.03%) | (30.62%) | (18.69%) | |
Free Cash Flow Yield |
(29.47%) | (24.86%) | (26.15%) | (14.33%) | |
Revenue per Share |
0.25 | 0.26 | 0.34 | 0.18 | |
Operating CF per Share |
(0.52) | (0.70) | (0.43) | (0.35) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.52) | (0.70) | (0.44) | (0.36) | |
Cash per Share |
2.47 | 1.41 | 2.26 | 2.48 | |
Shareholders Equity per Share |
1.56 | 0.75 | 1.46 | 1.74 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.56 | 0.75 | 1.46 | 1.74 | |
Free Cash Flow |
(30.35) | (32.14) | (18.36) | (15.98) | |
Working Capital |
141.78 | 65.96 | 93.19 | 110.20 | |
Capital Expenditures |
(0.22) | (0.11) | (0.39) | (0.16) | |
Net Current Asset Value |
79.93 | 23.76 | 52.31 | 69.52 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.03 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
7.71 | 9.62 | 9.20 | 5.61 | |
Average Payables |
3.55 | 2.60 | 3.63 | 4.02 | |
Average Inventory |
6.59 | 6.41 | 5.56 | 4.77 | |
Average Assets |
163.55 | 95.03 | 113.35 | 118.13 | |
Average Common Equity |
92.52 | 34.77 | 22.25 | 30.49 |
Columns are period end dates